OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Asaf Biber, Michal Mandelboim, Geva Harmelin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
Asaf Biber, Michal Mandelboim, Geva Harmelin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
Showing 17 citing articles:
Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 156
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 156
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 140
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 140
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 123
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 123
Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs
Raghava Kalyan Maddukuri, Madhavi Latha Desimalla, Reshma Banavathu, et al.
Indian Journal of Community Medicine (2025) Vol. 50, Iss. 1, pp. 9-19
Open Access
Raghava Kalyan Maddukuri, Madhavi Latha Desimalla, Reshma Banavathu, et al.
Indian Journal of Community Medicine (2025) Vol. 50, Iss. 1, pp. 9-19
Open Access
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results
Ariel Izcovich, Sasha Peiris, Martín Ragusa, et al.
Journal of Clinical Epidemiology (2021) Vol. 144, pp. 43-55
Open Access | Times Cited: 25
Ariel Izcovich, Sasha Peiris, Martín Ragusa, et al.
Journal of Clinical Epidemiology (2021) Vol. 144, pp. 43-55
Open Access | Times Cited: 25
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin Treatment in COVID-19 Patients
Smruti Karale, Vikas Bansal, Janaki Makadia, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 15
Smruti Karale, Vikas Bansal, Janaki Makadia, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 15
Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study
José Morgenstern, José N Redondo, A Landaluce Olavarria, et al.
Cureus (2021)
Open Access | Times Cited: 13
José Morgenstern, José N Redondo, A Landaluce Olavarria, et al.
Cureus (2021)
Open Access | Times Cited: 13
Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
Does ivermectin have a place in the treatment of mild Covid-19?
Eli Schwartz
New Microbes and New Infections (2022) Vol. 46, pp. 100985-100985
Open Access | Times Cited: 4
Eli Schwartz
New Microbes and New Infections (2022) Vol. 46, pp. 100985-100985
Open Access | Times Cited: 4
Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients
Marcos Mayer, Alejandro Krolewiecki, Alejandro Ferrero, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 3
Marcos Mayer, Alejandro Krolewiecki, Alejandro Ferrero, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 3
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review
Ariel Izcovich, Sasha Peiris, Martín Ragusa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Ariel Izcovich, Sasha Peiris, Martín Ragusa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Ivermectin in COVID-19 Management: What is the Current Evidence?
Madhavi Eerike, Gerard Marshall Raj, Rekha Priyadarshini, et al.
Infectious Disorders - Drug Targets (2022) Vol. 22, Iss. 4
Closed Access | Times Cited: 1
Madhavi Eerike, Gerard Marshall Raj, Rekha Priyadarshini, et al.
Infectious Disorders - Drug Targets (2022) Vol. 22, Iss. 4
Closed Access | Times Cited: 1
Systematic Review and Meta-analysis of Ivermectin for Treatment of COVID-19: Evidence Beyond the Hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
Research Square (Research Square) (2022)
Open Access
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
Research Square (Research Square) (2022)
Open Access
Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study
Morteza Shakhsi Niaee, Leila Zolghadr, Zahra Hosseinkhani, et al.
Iranian Journal of Science and Technology Transactions A Science (2022) Vol. 46, Iss. 5, pp. 1369-1375
Open Access
Morteza Shakhsi Niaee, Leila Zolghadr, Zahra Hosseinkhani, et al.
Iranian Journal of Science and Technology Transactions A Science (2022) Vol. 46, Iss. 5, pp. 1369-1375
Open Access
Pre-hospital Management of COVID-19: Looking for a Future Perspective
Davide Salmi, Ingrid Andreea Ilie, Nadia Pagnoncelli, et al.
Springer eBooks (2022), pp. 395-419
Closed Access
Davide Salmi, Ingrid Andreea Ilie, Nadia Pagnoncelli, et al.
Springer eBooks (2022), pp. 395-419
Closed Access
Reposicionamiento de ivermectina frente a COVID-19: evidencias científicas que avalan su potencial preventivo y terapéutico
A. Lifschitz, Luis E. Álvarez, Laura Ceballos, et al.
FAVE Sección Ciencias Veterinarias (2021) Vol. 20, Iss. Suppl., pp. 9-19
Open Access
A. Lifschitz, Luis E. Álvarez, Laura Ceballos, et al.
FAVE Sección Ciencias Veterinarias (2021) Vol. 20, Iss. Suppl., pp. 9-19
Open Access
